Prognostic value of dobutamine stress echocardiography: A South African experience.
AP, D., L, S., A, E., A, D.L., L, d.P., B, F., PA, B., & P, v.d.B. (2026). Prognostic value of dobutamine stress echocardiography: A South African experience.. Cardiovascular journal of Africa. https://doi.org/10.5830/CVJA-2025-115
AP D, L S, A E, A DL, L dP, B F, et al. Prognostic value of dobutamine stress echocardiography: A South African experience.. Cardiovascular journal of Africa. 2026; doi: 10.5830/CVJA-2025-115
AP D, L S, A E, et al. Prognostic value of dobutamine stress echocardiography: A South African experience.[J]. Cardiovascular journal of Africa. 2026. DOI: 10.5830/CVJA-2025-115.
@article{ap2026,
author = {Dippenaar AP and Scherman L and Espach A and De Lange A and du Pisanie L and Franckeiss B and Brink PA and van der Bijl P},
title = {Prognostic value of dobutamine stress echocardiography: A South African experience.},
journal = {Cardiovascular journal of Africa},
year = {2026},
doi = {10.5830/CVJA-2025-115},
note = {PMID: 42345272},
}
TY - JOUR AU - Dippenaar AP AU - Scherman L AU - Espach A AU - De Lange A AU - du Pisanie L AU - Franckeiss B AU - Brink PA AU - van der Bijl P TI - Prognostic value of dobutamine stress echocardiography: A South African experience. T2 - Cardiovascular journal of Africa PY - 2026 DO - 10.5830/CVJA-2025-115 AN - PMID:42345272 ER -
BACKGROUND: Dobutamine stress echocardiography (DSE) is a well-established modality for the diagnosis and risk-stratification of coronary artery disease, but no prognostic data have been reported from Southern Africa. OBJECTIVES: We investigated the prognostic utility of a South African DSE programme and compared the results to larger, internationals series. METHODS: All patients under going DSE from 2019 to 2023 at a single South African centre were included. A new wall motion abnormality (≥ 2 segments) signified inducible ischaemia. RESULTS: 166 patients (median age 65 ± 11years, 69% male) were analysed. 52 patients (31%) had diabetes mellitus, 155 (93%) had dyslipidaemia and 35 (21%) were smokers. 48 (29%) patients had received previous percutaneous revascularization and 10 (6%) coronary artery bypass surgery. During a median follow-up of 36 ± 7 months, 33 (20%) patients died or underwent coronary artery revascularization. Individuals with demonstrable, inducible ischaemia, experienced a higher rate of all-cause mortality or revascularization during follow-up. CONCLUSION: The prognostic value of a South African DSE programme for all-cause mortality and revascularization was demonstrated for the first time. Data are aligned with large, international series with comparable follow-up time.